Abbott Launches Trial Of First-Of-A-Kind Resorbable Scaffold For Critical Limb Ischemia
Executive Summary
The Esprit BTK everolimus-eluting resorbable scaffold is designed to treat arteries below the knee. No stents or drug-coated balloons are currently FDA-approved for that indication.
You may also be interested in...
Exec Chat: Abbott Invests In Outreach To Underrepresented Populations
Jennifer Jones-McMeans, Divisional Vice President of Global Clinical Affairs at Abbott’s vascular device business, talked to Medtech Insight about her company’s ongoing efforts to diversify patient enrollment in clinical trials by communicating more effectively and compassionately with people in traditionally underrepresented demographic groups.
Abbott Wants To Expand Clinical Trial Access By Diversifying Investigator Community
The company’s plan to reduce barriers to clinical trial participation for underrepresented groups includes the creation of nearly 300 new scholarships at medical schools of historically black colleges and universities and minority nursing associations.
Start-Up Spotlight: Efemoral Begins Trial Of Peripheral Stent With Inter-Scaffold Gaps
The EFEMORAL I trial is the first-in-human study of the start-up company’s FlexStep technology in patients with symptomatic femoropopliteal artery disease.